by Madaline Spencer | May 6, 2024
Benjamin Barnes, MD, Augusta University, discusses how he approaches ALS patient conversations and an ongoing platform trial. Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease, is a motor neuron disease which leads to...
by Madaline Spencer | May 3, 2024
Sean Studer, MD, MSc, FCCP, Head of Medical Affairs at the US Pulmonary Hypertension Group, at Johnson & Johnson, discusses the changing treatment landscape of pulmonary arterial hypertension (PAH), including the approval of Opsynvi (macitentan plus tadalafil)....
by Madaline Spencer | May 1, 2024
Michael Hayden, PhD, CEO of Prilenia, discusses recent clinical trials testing pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington’s disease. ALS, also referred to as Lou Gehrig’s disease, is a motor neuron disease...
by Madaline Spencer | Apr 29, 2024
The U.S. Food and Drug Administration (FDA) has approved Xolremdi (mavorixafor), the first therapy to receive approval for the treatment of persons with WHIM syndrome. WHIM syndrome is an acronym for a rare immunodeficiency disorder with each letter...
by Madaline Spencer | Apr 25, 2024
Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, discusses neuromyelitis optica spectrum disorder (NMOSD) and the ongoing trial for a new app that can better monitor patients with NMOSD. NMOSD is an autoimmune disorder...
